Back from the dead: FierceBiotech Radio resurrects for the Battle of the Biotech Bands

Sanofi Genzyme band Led Zymmelin performing on stage
Before the Battle of the Biotech Bands, Led Zymmelin had never performed outside of Sanofi Genzyme. (Brian Malloy)

You asked and we listened—FierceBiotech Radio will return to the airwaves in 2018, after what will be a two-year hiatus. But for those of you who can’t wait that long, here’s a special “risen-from-the-grave” episode covering this year’s Battle of the Biotech Bands, an (almost) annual Boston tradition which sees bands from the biotech industry compete to win prize money for charity.

Four bands competed this year:

  • Semi Good Lookin’, representing Aquinnah Pharmaceuticals, Blueprint Medicines and Harmonic Lab Solutions, playing for the National Organization for Rare Disorders (NORD)
  • Led Zymmelin, representing Sanofi Genzyme, also playing for NORD
  • Life Size, representing GE Life Sciences, playing for the Michael J. Fox Foundation
  • Aural Gavage, representing Momenta Pharmaceuticals, playing for the Jolane Solomon Research Fund at Boston College

Download the episode on iTunes or Stitcher, or listen below. Let us know what you think, and what you'd like to hear about in future episodes at [email protected] or in the suggestion box below.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Song list:

  • Thrift Shop, by Macklemore & Ryan Lewis, performed by Semi Good Lookin’
  • I Love Rock N Roll, by Joan Jett & the Blackhearts, performed by Led Zymmelin
  • Don’t Stop Believin’, by Journey, performed by Led Zymmelin
  • Stop Draggin’ My Heart Around, by Stevie Nicks & Tom Petty, performed by Aural Gavage
  • I’ve Just Seen a Face, by the Beatles, performed by Aural Gavage

Editor's note: This story was edited to include a link to iTunes and Stitcher, and to update the email address.

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.